aacr

AACR 2023 Transgene presented exciting preclinical data on TG6050, an intravenous Invir.IO® oncolytic virus Donwload Press release (PDF) TG6002 en images

innovation box

Innovative technologies Push the boundaries of immunotherapy Transgene combines cutting-edge technologies, a multidisciplinary team and a prestigious international network. Discover our two therapeutic approaches Discover our technologies

TG4001 box

TG4001 A therapeutic vaccine in Phase II TG4001 targets HPV-induced anogenital cancers.   More information

myvac-box

One patient, one cancer, one vaccine With myvac®, Transgene enters the field of individualized immunotherapies with a unique virus-based immunotherapy platform.   myvac® video   Discover myvac®  Watch Professor C. Ottensmeier’s commentary on the first clinical results  

invirio-box

A new generation of products These innovative multifunctional OVs are able to modulate the tumor micro-environment to better attack cancer.   invir.IO® en image   Discover invir.IO®